	1.	Article Title: Higher incidence of acute symptomatic seizures in probable antibody-negative pediatric autoimmune encephalitis than in major antibody-positive autoimmune encephalitis
	•	Line(s): 1-2
	•	Section: Title
	•	Quote(s): “Higher incidence of acute symptomatic seizures in probable antibody-negative pediatric autoimmune encephalitis than in major antibody-positive autoimmune encephalitis”
	2.	Publication Year: 2024
	•	Line(s): 5
	•	Section: Journal Citation
	•	Quote(s): “Frontiers in Neurology, Published: 19 July 2024”
	3.	Region: Asia
	•	Line(s): 10-12
	•	Section: Author Affiliations
	•	Quote(s): “Osaka City General Hospital, Osaka, Japan; Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan”
	4.	Country: Japan
	•	Line(s): 10-12
	•	Section: Author Affiliations
	•	Quote(s): “Osaka City General Hospital, Osaka, Japan; Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan”
	5.	Study Coverage Area: Single-center study (Osaka City General Hospital, Japan)
	•	Line(s): 30-32
	•	Section: Methods
	•	Quote(s): “Eighteen consecutive pediatric patients with a diagnosis of probable Ab-negative AE who were referred to Osaka City General Hospital between 1 January 2015 and 31 March 2023 were included in this study.”
	6.	Study Design: Retrospective cohort study
	•	Line(s): 30-34
	•	Section: Methods
	•	Quote(s): “This was a retrospective cohort study comparing probable antibody-negative AE with NMDARE and MOGAD.”
	7.	Population Cohort: Pediatric patients diagnosed with autoimmune encephalitis (AE)
	•	Line(s): 30-34
	•	Section: Methods
	•	Quote(s): “Eighteen consecutive pediatric patients (age < 18 years) with a diagnosis of probable Ab-negative AE.”
	8.	Population Characteristics: Median age 8.1 years, 67% male
	•	Line(s): 90-92
	•	Section: Results
	•	Quote(s): “The median age at onset was 8.1 years (IQR 6.0-11.0), with males accounting for 67% (12/18).”
	9.	Data Source: Hospital medical records
	•	Line(s): 30-32
	•	Section: Methods
	•	Quote(s): “Clinical data were collected from 18 pediatric patients with AE at the Osaka City General Hospital.”
	10.	Prospective or Retrospective: Retrospective
	•	Line(s): 30
	•	Section: Methods
	•	Quote(s): “This was a retrospective cohort study.”
	11.	Sites or Centers Involved: Single center (Osaka City General Hospital)
	•	Line(s): 30-32
	•	Section: Methods
	•	Quote(s): “Osaka City General Hospital, Japan.”
	12.	Study Duration: January 2015 – March 2023
	•	Line(s): 30-32
	•	Section: Methods
	•	Quote(s): “Patients were included between 1 January 2015 and 31 March 2023.”
	13.	Population Ethnicity: NR
	14.	Disease Analysis: Autoimmune encephalitis (AE) and seizure outcomes
	•	Line(s): 27-30
	•	Section: Methods
	•	Quote(s): “This study compared the clinical features and outcomes of probable antibody-negative AE, NMDARE, and MOGAD.”
	15.	Classification or Diagnosis: Autoimmune Encephalitis International Working Group criteria
	•	Line(s): 82-86
	•	Section: Methods
	•	Quote(s): “The diagnosis of AE was based on criteria from the Autoimmune Encephalitis International Working Group, with slight modifications.”
	16.	Diagnosis Criteria Details: Probable antibody-negative AE classification based on clinical features, neuroinflammation markers, and absence of autoantibodies
	•	Line(s): 82-86
	•	Section: Methods
	•	Quote(s): “Probable Ab-negative AE cases met criteria including acute neurological symptoms, neuroinflammation evidence, and negative autoantibody results.”
	17.	Disease Phase: Acute or subacute
	•	Line(s): 92-94
	•	Section: Results
	•	Quote(s): “Patients in the probable Ab-negative AE group exhibited acute symptomatic seizures significantly more frequently.”
	18.	Cohort Age Group: Pediatric (median 8.1 years)
	•	Line(s): 90-92
	•	Section: Results
	•	Quote(s): “The median age at onset was 8.1 years (IQR 6.0-11.0).”
	19.	Female Percentage in Cohort: 33%
	•	Line(s): 90-92
	•	Section: Results
	•	Quote(s): “With males accounting for 67% (12/18), females accounted for 33% (6/18).”
	20.	Patient Number of Autoimmune Encephalitis: 18 patients
	•	Line(s): 94
	•	Section: Results
	•	Quote(s): “Eighteen pediatric patients were included in the probable Ab-negative AE group.”
	•	Subtypes and Patient Numbers:
	•	Probable antibody-negative AE: 18 patients
	•	Anti-NMDAR encephalitis (NMDARE): 13 patients
	•	MOGAD: 13 patients
	21.	Follow-up Period: Median 5.0 years (IQR 3.5-6.7)
	•	Line(s): 213-215
	•	Section: Results
	•	Quote(s): “Follow-up duration was median 5.0 years (IQR 3.5-6.7).”
	22.	Age of Patients by Subtype:
	•	Probable antibody-negative AE:
	•	Median: 8.1 years
	•	IQR: 6.0 - 11.0
	23.	Age of Diagnosis by Subtype: NR